GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.GeneDx Stock Plummets 50% as Guidance Slashed on Reimbursement Woes
GeneDx faces investigation after 50% stock decline following massive guidance cut, operational losses, and $31.3M goodwill write-down on weak reimbursement rates.
WGSWGSWWclass action lawsuitearnings miss